OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
18-80 years of age
Average of 1-4 breakthrough pain episodes per day
Histologically documented diagnosis of a malignant solid tumor or hematological malignancy
Primary breakthrough pain is not related to cancer in any way
Opioid or fentanyl intolerance
Chronic obstructive pulmonary disease (COPD) or heart disease
Sleep apnea or active brain metastases with increased cranial pressure